Paracetamol & Codeine Aspar Pharmaceuticals (Paracetamol, Codeine Phosphate Hemihydrate)

Paracetamol and Codeine Phosphate Hemihydrate, the active ingredient in Paracetamol & Codeine Aspar Pharmaceuticals, is an analgesic presented as an oral dosage form for oral use. It provides relief of mild to moderate pain and reduces fever in adults and children when prescribed.

GNH USA supplies Paracetamol & Codeine Aspar Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and timely delivery across multiple regions. The company adheres to stringent quality standards to ensure product integrity.

Paracetamol and Codeine act on pain and fever pathways to provide symptomatic relief. - Mild to moderate pain: reduces pain intensity in conditions such as headache, dental pain, musculoskeletal discomfort, or postoperative pain. - Fever: lowers elevated body temperature associated with infections or inflammatory conditions. - Cough: suppresses the cough reflex through the opioid component, useful in short‑term management of non‑productive cough. - Migraine (adjunct): provides analgesic effect that may complement specific migraine therapies.

Paracetamol and Codeine may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Nausea: feeling of stomach upset or urge to vomit. - Dizziness: light‑headed sensation or loss of balance. - Constipation: reduced bowel movements or hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dry mouth: reduced salivation causing throat discomfort. Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatic injury: signs of liver damage such as jaundice or elevated enzymes. - Dependence or abuse potential: risk of developing opioid use disorder with prolonged use. - Opioid‑induced constipation leading to bowel obstruction (rare).

When prescribing Paracetamol & Codeine, clinicians should consider several safety precautions to minimise risk. - Assess liver function: avoid use in patients with severe hepatic impairment or active liver disease. - Evaluate renal function: dose adjustment may be needed for severe renal insufficiency. - Screen for opioid sensitivity: avoid in individuals with known hypersensitivity to codeine or other opioids. - Limit concurrent CNS depressants: caution when used with alcohol, benzodiazepines, or antihistamines. - Monitor for dependence: use the lowest effective dose for the shortest duration to reduce abuse risk. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Paracetamol & Codeine can interact with other medicines, altering efficacy or safety. Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome and hypertensive crisis. - Other opioids or strong CNS depressants: additive respiratory depression. - Alcohol: enhances sedative effects and risk of liver toxicity. - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): reduce conversion of codeine to morphine, decreasing analgesia. Moderate Interactions (Monitor Closely): - Antihistamines: may increase drowsiness and dizziness. - Benzodiazepines: can potentiate sedation and respiratory effects. - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Anticoagulants (warfarin): paracetamol may enhance anticoagulant effect, requiring INR monitoring.